Clinical trials
Cholangitis clinical trials
Below are recruiting cholangitis clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04181138Recruiting
Study of childhood primary sclerosing cholangitis types
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
Los Angeles, CaliforniaAges 2–25 - NCT03146936Recruiting
Study of people with primary sclerosing cholangitis in Switzerland
This study follows people diagnosed with primary sclerosing cholangitis to better understand the condition over time. It may help doctors learn which factors affect health and care, and improve future treatment decisions.
Lugano, Canton TicinoAges Any age - NCT06051617RecruitingPhase 3
Testing seladelpar for PBC with compensated cirrhosis
This study tests an experimental oral drug called seladelpar for people with PBC who also have cirrhosis that is well-controlled. The goal is to see if it helps improve liver health and manage symptoms without causing serious side effects.
Birmingham, AlabamaAges 18 years+ - NCT03566797Recruiting
Study in ICU patients with prolonged breathing support
This study looks at outcomes in adults who need breathing support for at least 5 days in intensive care. It may help clinicians better understand and manage complications in this critical illness group.
GrazAges 18 years+ - NCT07667166Recruiting
Measuring outcomes in acute cholangitis
This study looks at how well people recover from acute cholangitis, a serious bile duct infection. It will create a tool to track the impact of treatment, such as drainage procedures, to help doctors improve care.
Hyderabad, TelanganaAges 18–80 - NCT06447168Recruiting
Observing elafibranor in everyday care for PBC
This study follows people with primary biliary cholangitis (PBC) who are already taking or starting elafibranor, to see how well it works and how safe it is in everyday life. No extra treatments or tests are required beyond what your doctor normally does.
Coronado, CaliforniaAges Any age - NCT07387549RecruitingPhase 3
Elafibranor for primary sclerosing cholangitis
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
Chandler, ArizonaAges 18–75 - NCT06723275Recruiting
A study on liver transplant for different liver diseases
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
Ghent, BelgiumAges 18–70 - NCT06675604Recruiting
Liver transplant data collection study
This study collects data from adults listed for liver transplants due to severe liver disease or liver cancer. It aims to improve transplant care by learning from real-world patient information.
ViennaAges 18–70 - NCT07216235RecruitingPhase 3
Long-term study of saroglitazar for PBC with cirrhosis
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Marietta, GeorgiaAges 18 years+ - NCT04685200Recruiting
Study causes of primary sclerosing cholangitis using body scans
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
Bethesda, MarylandAges 18–90 - NCT05050136RecruitingPhase 2
Volixibat trial for itch from primary biliary cholangitis
This Phase 2 study tests whether volixibat can safely reduce itching caused by primary biliary cholangitis (PBC). If you have PBC-related itch that persists, this trial may help you find a new treatment option.
Coronado, CaliforniaAges 18 years+ - NCT05151809Recruiting
Italy-wide database study for adults with primary biliary cholangitis
This study creates a national registry (database) of adults in Italy living with primary biliary cholangitis (PBC). Being included can help doctors better understand the condition and improve future care.
AnconaAges 18 years+ - NCT05295680RecruitingPhase 2
Oral hymecromone for primary sclerosing cholangitis
This trial tests whether taking hymecromone by mouth can improve primary sclerosing cholangitis (a liver/bile duct condition). It may help by targeting inflammation and bile duct problems, especially in people who are stable on other medicines.
Redwood City, CaliforniaAges 14–75 - NCT05618145Recruiting
Join a national study database for primary sclerosing cholangitis
This study creates a national database for people diagnosed with primary sclerosing cholangitis (PSC). It may help researchers learn more about the condition by collecting health information from participants.
AnconaAges 17 years+ - NCT05749822RecruitingPhase 2/Phase 3
Fenofibrate for primary biliary cholangitis with stable cirrhosis
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
Beijing, Beijing MunicipalityAges 18–75 - NCT05751967RecruitingPhase 3
Fenofibrate plus ursodeoxycholic acid for primary biliary cholangitis
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
Lanzhou, GansuAges 18–75 - NCT05876182RecruitingPhase 2
Vancomycin for primary sclerosing cholangitis
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
Monza, Monza E BrianzaAges 15–70 - NCT05912387RecruitingEarly Phase 1
Testing statin treatment in primary sclerosing cholangitis
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
Stanford, CaliforniaAges 18–80 - NCT05919433Recruiting
Program to find people with primary biliary cholangitis
This trial is testing a “find patients who are missing from care” program for people with primary biliary cholangitis (PBC). It may help connect you to follow-up sooner if you’ve been hard to reach through usual clinic records.
Terrassa, BarcelonaAges 18 years+ - NCT05925309Recruiting
Oral antibiotics to prevent bile duct inflammation after Kasai surgery
This trial studies whether giving oral antibiotics before symptoms start can lower the chance of cholangitis (bile duct infection/inflammation) after Kasai portoenterostomy. It may help protect your child’s bile flow and reduce painful or serious infections after surgery.
Shanghai, Shanghai MunicipalityAges 2 weeks–3 months - NCT06286709RecruitingPhase 2
Fecal transplant for PSC and colitis
This trial tests whether a fecal (stool) transplant from a healthy donor can help people with both PSC and inflammatory bowel disease. It aims to see if the treatment can improve liver health and reduce inflammation. You must have early to moderate liver scarring and be on stable medications.
BirminghamAges 18 years+ - NCT06365424RecruitingPhase 2/Phase 3
Fenofibrate for Primary Biliary Cholangitis (PBC)
This trial tests whether the drug fenofibrate can help people with primary biliary cholangitis (PBC), a chronic liver disease. It is for patients who have already taken fenofibrate in a previous study and want to continue treatment.
Xi'an, ShaanxiAges 18–75 - NCT06755151RecruitingPhase 3
Fenofibrate for primary biliary cholangitis: a real-world study
This study tests fenofibrate, a medicine that may help lower liver enzymes in people with primary biliary cholangitis (PBC). It looks at how well the drug works in everyday medical practice.
Xi'an, ShaanxiAges 18–75
Hear when a new Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangitis?
- Yes. Clin2 currently lists 63 recruiting cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.